You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBalsalazide
Accession NumberDB01014  (APRD00141)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBalsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of Ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.
Structure
Thumb
Synonyms
(e)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid
(e)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid
3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid
5-[4-(2-Carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
Balsalazida
Balsalazido
Balsalazidum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Balsalazide DisodiumCapsule750 mg/1OralClinical Solutions Wholesale, Llc2000-07-18Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralOceanside Pharmaceuticals2000-07-18Not applicableUs
ColazalCapsule750 mg/1OralCardinal Health2000-07-18Not applicableUs
ColazalCapsule750 mg/1OralSalix Pharmaceuticals, Inc2000-07-18Not applicableUs
GiazoTablet, film coated1.1 g/1OralSalix Pharmaceuticals, Inc2012-02-02Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Balsalazide DisodiumCapsule750 mg/1OralApotex Corp.2007-12-28Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralMylan Pharmaceuticals Inc.2007-12-28Not applicableUs
Balsalazide DisodiumTablet1.1 g/1OralPar Pharmaceutical Inc.2015-07-01Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralAv Kare, Inc.2016-06-29Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralAv Pak2014-11-06Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralWest Ward Pharmaceuticals Corp.2007-12-28Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralPhysicians Total Care, Inc.2010-08-18Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralClinical Solutions Wholesale2007-12-28Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralAmerican Health Packaging2014-07-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ColazideNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Balsalazide disodium
ThumbNot applicableDBSALT000835
Categories
UNIIP80AL8J7ZP
CAS number80573-04-2
WeightAverage: 357.3175
Monoisotopic: 357.096085227
Chemical FormulaC17H15N3O6
InChI KeyIPOKCKJONYRRHP-FMQUCBEESA-N
InChI
InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+
IUPAC Name
5-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid
SMILES
OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O
Pharmacology
IndicationFor the treatment of mildly to moderately active ulcerative colitis.
Structured Indications
PharmacodynamicsBalsalazide is a prodrug that has little or no pharmacologic activity until it is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and the intert 4-aminobenzoyl-(beta)-alanine. As a result, the spectrum of pharmacologic activity of balsalazide is similar to that of mesalamine.
Mechanism of actionThe mechanism of action of 5-aminosalicylic acid is unknown, but appears exert its anti-inflammatory effects locally (in the GI tract) rather than systemically. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (catalyzes the formation of prostaglandin precursors from arachidonic acid), and through the lipoxygenase pathways (catalyzes the formation of leukotrienes and hydroxyeicosatetraenoic acids from arachidonic acid and its metabolites), is increased in patients with chronic inflammatory bowel disease. Therefore, it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon through both the inhibition of cyclooxygenase and lipoxygenase.
TargetKindPharmacological actionActionsOrganismUniProt ID
Peroxisome proliferator-activated receptor gammaProteinyes
agonist
HumanP37231 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Arachidonate 5-lipoxygenaseProteinyes
inhibitor
HumanP09917 details
Related Articles
AbsorptionLow and variable, intact balsalazide is poorly absorbed systemically.
Volume of distributionNot Available
Protein binding≥99%
Metabolism

Cleaved in the colon via bacterial azoreduction to 5–aminosalicylic acid (5–ASA) and 4–aminobenzoyl-beta-alanine, the inactive carrier moiety.

SubstrateEnzymesProduct
Balsalazide
5-aminosalicylic acidDetails
Balsalazide
Not Available
4-aminobenzoyl-(beta)-alanineDetails
Route of eliminationThe products of the azoreduction of this compound, 5-ASA and 4-aminobenzoyl-ß-alanine, and their N-acetylated metabolites have been identified in plasma, urine and feces. Following single-dose administration of 2.25 g COLAZAL (three 750 mg capsules) under fasting conditions in healthy subjects, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.20%, 0.22% and 10.2%, respectively.
Half lifeHalf-life could not be determined.
ClearanceNot Available
ToxicityA single oral dose of balsalazide disodium at 5 grams/kg or 4-aminobenzoyl-(beta)-alanine, a metabolite of balsalazide disodium, at 1 gram/kg was non-lethal in mice and rats. No symptoms of acute toxicity were seen at these doses.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Balsalazide is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Balsalazide is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Balsalazide is combined with 5-androstenedione.Experimental, Illicit
AbciximabBalsalazide may increase the anticoagulant activities of Abciximab.Approved
AcarboseBalsalazide may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololBalsalazide may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacAceclofenac may increase the nephrotoxic activities of Balsalazide.Approved
AcenocoumarolBalsalazide may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneAcetovanillone may increase the nephrotoxic activities of Balsalazide.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved
AclarubicinBalsalazide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneAdapalene may increase the nephrotoxic activities of Balsalazide.Approved
AlbiglutideBalsalazide may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Alendronic acid.Approved
AliskirenBalsalazide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlogliptinBalsalazide may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololBalsalazide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Balsalazide.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Alteplase.Approved
ALX-0081The risk or severity of adverse effects can be increased when Balsalazide is combined with ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Amcinonide.Approved
AmikacinBalsalazide may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideBalsalazide may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Balsalazide.Approved
Ammonium chlorideThe serum concentration of Balsalazide can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AmrubicinBalsalazide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Balsalazide.Approved
AncrodBalsalazide may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Balsalazide is combined with Anecortave.Investigational
AnisodamineAnisodamine may increase the nephrotoxic activities of Balsalazide.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Anistreplase.Approved
annamycinBalsalazide may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may increase the nephrotoxic activities of Balsalazide.Approved
Antithrombin III humanBalsalazide may increase the anticoagulant activities of Antithrombin III human.Approved
AnvirzelThe serum concentration of Anvirzel can be decreased when it is combined with Balsalazide.Investigational
Aop200704Balsalazide may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanBalsalazide may increase the anticoagulant activities of Apixaban.Approved
ApramycinBalsalazide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastApremilast may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
ArbekacinBalsalazide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ardeparin.Approved, Withdrawn
ArgatrobanBalsalazide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololBalsalazide may decrease the antihypertensive activities of Arotinolol.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Astaxanthin.Investigational
AtenololBalsalazide may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneAzapropazone may increase the nephrotoxic activities of Balsalazide.Withdrawn
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Balsalazide.Approved
AzelastineAzelastine may increase the nephrotoxic activities of Balsalazide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Balsalazide.Approved
BatroxobinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Batroxobin.Experimental
BecaplerminBalsalazide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololBalsalazide may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Bemiparin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Balsalazide.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Balsalazide.Approved
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Balsalazide.Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Balsalazide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Betamethasone.Approved, Vet Approved
BetaxololBalsalazide may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidBetulinic Acid may increase the nephrotoxic activities of Balsalazide.Investigational
BevantololBalsalazide may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Balsalazide.Approved, Investigational
BisoprololBalsalazide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinBalsalazide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololBalsalazide may decrease the antihypertensive activities of Bopindolol.Approved
BrinzolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Brinzolamide.Approved
BromfenacBromfenac may increase the nephrotoxic activities of Balsalazide.Approved
BromocriptineBalsalazide may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the nephrotoxic activities of Balsalazide.Investigational
BucindololBalsalazide may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Budesonide.Approved
BufuralolBalsalazide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideBalsalazide may decrease the diuretic activities of Bumetanide.Approved
BupranololBalsalazide may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Balsalazide.Investigational
CanagliflozinBalsalazide may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Balsalazide.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Balsalazide.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Balsalazide.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Balsalazide.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Balsalazide.Approved
CarprofenCarprofen may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved, Withdrawn
CarteololBalsalazide may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolBalsalazide may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the nephrotoxic activities of Balsalazide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Celecoxib.Approved, Investigational
CeliprololBalsalazide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Certoparin.Approved
ChloroquineChloroquine may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Balsalazide.Approved, Vet Approved
ChlorpropamideBalsalazide may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Balsalazide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Balsalazide.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Balsalazide.Approved
CinoxacinBalsalazide may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinBalsalazide may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidBalsalazide may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the nephrotoxic activities of Balsalazide.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Balsalazide.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Balsalazide.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cortisone acetate.Approved
CurcuminCurcumin may increase the nephrotoxic activities of Balsalazide.Investigational
CyclosporineBalsalazide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the nephrotoxic activities of Balsalazide.Investigational
Dabigatran etexilateBalsalazide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dalteparin.Approved
DanaparoidBalsalazide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinBalsalazide may increase the hypoglycemic activities of Dapagliflozin.Approved
DaunorubicinBalsalazide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Balsalazide is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Balsalazide.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Balsalazide is combined with dehydroepiandrosterone sulfate.Investigational
dersalazineBalsalazide may increase the anticoagulant activities of dersalazine.Investigational
DesirudinBalsalazide may increase the anticoagulant activities of Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Balsalazide.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Balsalazide.Approved
DextranBalsalazide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Balsalazide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Balsalazide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Balsalazide may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Balsalazide.Approved, Vet Approved
DiclofenacDiclofenac may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Diclofenamide.Approved
DicoumarolBalsalazide may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the nephrotoxic activities of Balsalazide.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Balsalazide.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Balsalazide.Approved
DihydrostreptomycinBalsalazide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Balsalazide.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Balsalazide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Balsalazide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Balsalazide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Balsalazide.Approved
DisopyramideBalsalazide may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dorzolamide.Approved
DoxorubicinBalsalazide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneBalsalazide may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Balsalazide is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the nephrotoxic activities of Balsalazide.Approved
DulaglutideBalsalazide may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the nephrotoxic activities of Balsalazide.Investigational
E6201E6201 may increase the nephrotoxic activities of Balsalazide.Investigational
EbselenEbselen may increase the nephrotoxic activities of Balsalazide.Investigational
Edetic AcidBalsalazide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBalsalazide may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinBalsalazide may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Balsalazide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Balsalazide.Approved
EnoxacinBalsalazide may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Balsalazide.Approved, Investigational
EpirizoleEpirizole may increase the nephrotoxic activities of Balsalazide.Approved
EpirubicinBalsalazide may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneBalsalazide may decrease the antihypertensive activities of Eplerenone.Approved
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Balsalazide.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Balsalazide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Balsalazide.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Balsalazide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Balsalazide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Equilin.Approved
EsmololBalsalazide may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Estrone sulfate.Approved
Etacrynic acidBalsalazide may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptEtanercept may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
EthoxzolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateBalsalazide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the nephrotoxic activities of Balsalazide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etoricoxib.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Balsalazide.Approved
ExenatideBalsalazide may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the nephrotoxic activities of Balsalazide.Investigational
FenbufenFenbufen may increase the nephrotoxic activities of Balsalazide.Approved
FenoprofenFenoprofen may increase the nephrotoxic activities of Balsalazide.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Balsalazide.Vet Approved
FibrinolysinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fibrinolysin.Approved
FleroxacinBalsalazide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Balsalazide.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fludrocortisone.Approved
FluindioneBalsalazide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineBalsalazide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flunisolide.Approved, Investigational
FlunixinFlunixin may increase the nephrotoxic activities of Balsalazide.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Balsalazide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flurandrenolide.Approved
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Balsalazide.Approved, Nutraceutical, Vet Approved
FondaparinuxBalsalazide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumBalsalazide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Balsalazide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Balsalazide.Approved
FramycetinBalsalazide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideBalsalazide may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateBalsalazide may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinBalsalazide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinBalsalazide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Balsalazide.Approved, Withdrawn
GemifloxacinBalsalazide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinBalsalazide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinBalsalazide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ABalsalazide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Balsalazide.Approved, Nutraceutical
GliclazideBalsalazide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBalsalazide may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBalsalazide may increase the hypoglycemic activities of Glipizide.Approved
GlyburideBalsalazide may increase the hypoglycemic activities of Glyburide.Approved
GrepafloxacinBalsalazide may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Balsalazide is combined with HE3286.Investigational
HeparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Heparin.Approved, Investigational
HigenamineHigenamine may increase the nephrotoxic activities of Balsalazide.Investigational
HirulogBalsalazide may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the nephrotoxic activities of Balsalazide.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Balsalazide.Approved, Investigational
HydralazineBalsalazide may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Balsalazide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Balsalazide.Approved
Hygromycin BBalsalazide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Balsalazide.Approved, Investigational
IbuprofenIbuprofen may increase the nephrotoxic activities of Balsalazide.Approved
IbuproxamIbuproxam may increase the nephrotoxic activities of Balsalazide.Withdrawn
IcatibantIcatibant may increase the nephrotoxic activities of Balsalazide.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Balsalazide.Approved, Nutraceutical
IdarubicinBalsalazide may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxBalsalazide may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Balsalazide.Approved, Withdrawn
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Balsalazide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Balsalazide.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Balsalazide.Approved
IndenololBalsalazide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Balsalazide is combined with Indobufen.Investigational
IndomethacinIndomethacin may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
IndoprofenIndoprofen may increase the nephrotoxic activities of Balsalazide.Withdrawn
INNO-206Balsalazide may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
Insulin AspartBalsalazide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirBalsalazide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineBalsalazide may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineBalsalazide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanBalsalazide may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproBalsalazide may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Balsalazide.Approved, Investigational
IsoxicamIsoxicam may increase the nephrotoxic activities of Balsalazide.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Balsalazide is combined with Istaroxime.Investigational
KanamycinBalsalazide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
Kct 0809The risk or severity of adverse effects can be increased when Balsalazide is combined with Kct 0809.Investigational
KebuzoneKebuzone may increase the nephrotoxic activities of Balsalazide.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Balsalazide.Investigational
KetoprofenKetoprofen may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Balsalazide.Approved
KetorolacKetorolac may increase the nephrotoxic activities of Balsalazide.Approved
LabetalolBalsalazide may decrease the antihypertensive activities of Labetalol.Approved
LanreotideBalsalazide may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Balsalazide.Approved, Investigational
LeflunomideLeflunomide may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
LepirudinBalsalazide may increase the anticoagulant activities of Lepirudin.Approved
LevobunololBalsalazide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinBalsalazide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Balsalazide.Approved
LiraglutideBalsalazide may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Balsalazide.Approved, Investigational
LisofyllineLisofylline may increase the nephrotoxic activities of Balsalazide.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Balsalazide.Approved
LomefloxacinBalsalazide may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamLornoxicam may increase the nephrotoxic activities of Balsalazide.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Balsalazide.Approved
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Balsalazide.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Balsalazide.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Balsalazide.Vet Approved
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Balsalazide.Approved
MasoprocolMasoprocol may increase the nephrotoxic activities of Balsalazide.Approved
ME-609The risk or severity of adverse effects can be increased when Balsalazide is combined with ME-609.Investigational
MecaserminBalsalazide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Medrysone.Approved
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Balsalazide.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Melengestrol.Vet Approved
MeloxicamMeloxicam may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Balsalazide.Approved
MesalazineMesalazine may increase the nephrotoxic activities of Balsalazide.Approved
MetamizoleMetamizole may increase the nephrotoxic activities of Balsalazide.Withdrawn
MetforminBalsalazide may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Balsalazide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Balsalazide.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Methylprednisolone.Approved, Vet Approved
MetipranololBalsalazide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Balsalazide.Approved
MetoprololBalsalazide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideBalsalazide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneBalsalazide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolBalsalazide may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Balsalazide.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Balsalazide.Approved
MizoribineMizoribine may increase the nephrotoxic activities of Balsalazide.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Balsalazide.Approved
MometasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Balsalazide.Approved
MoxifloxacinBalsalazide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the nephrotoxic activities of Balsalazide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Nabumetone.Approved
NadololBalsalazide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Nadroparin.Approved
NafamostatNafamostat may increase the nephrotoxic activities of Balsalazide.Investigational
NaftifineNaftifine may increase the nephrotoxic activities of Balsalazide.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Balsalazide.Investigational
Nalidixic AcidBalsalazide may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenNaproxen may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved
NateglinideBalsalazide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Balsalazide is combined with NCX 1022.Investigational
NCX 4016NCX 4016 may increase the nephrotoxic activities of Balsalazide.Investigational
NeamineBalsalazide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinBalsalazide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinBalsalazide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacNepafenac may increase the nephrotoxic activities of Balsalazide.Approved
NetilmicinBalsalazide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Balsalazide.Approved
NimesulideNimesulide may increase the nephrotoxic activities of Balsalazide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Balsalazide.Investigational
NorfloxacinBalsalazide may increase the neuroexcitatory activities of Norfloxacin.Approved
OctreotideBalsalazide may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OfloxacinBalsalazide may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Balsalazide.Approved, Investigational
OlopatadineOlopatadine may increase the nephrotoxic activities of Balsalazide.Approved
OlsalazineBalsalazide may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Balsalazide.Investigational
OrgoteinOrgotein may increase the nephrotoxic activities of Balsalazide.Vet Approved
OtamixabanBalsalazide may increase the anticoagulant activities of Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Balsalazide.Approved
OxaprozinOxaprozin may increase the nephrotoxic activities of Balsalazide.Approved
OxprenololBalsalazide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Balsalazide.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Parnaparin.Approved
ParomomycinBalsalazide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PasireotideBalsalazide may increase the hypoglycemic activities of Pasireotide.Approved
PazufloxacinBalsalazide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinBalsalazide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololBalsalazide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineBalsalazide may increase the hypoglycemic activities of Pentamidine.Approved
Pentosan PolysulfateBalsalazide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Balsalazide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Balsalazide.Approved
PhenindioneBalsalazide may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonBalsalazide may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
PindololBalsalazide may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneBalsalazide may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirarubicinBalsalazide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideBalsalazide may decrease the diuretic activities of Piretanide.Experimental
PirfenidonePirfenidone may increase the nephrotoxic activities of Balsalazide.Investigational
PiroxicamPiroxicam may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
PlasminThe risk or severity of adverse effects can be increased when Balsalazide is combined with Plasmin.Investigational
PlicamycinBalsalazide may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Balsalazide.Approved
PractololBalsalazide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Balsalazide.Approved
PramlintideBalsalazide may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prasterone.Approved, Nutraceutical
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Balsalazide.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Balsalazide can be increased when it is combined with Probenecid.Approved
PropacetamolPropacetamol may increase the nephrotoxic activities of Balsalazide.Approved
PropranololBalsalazide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Balsalazide.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Balsalazide.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Balsalazide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Balsalazide.Vet Approved
Protein CBalsalazide may increase the anticoagulant activities of Protein C.Approved
Protein S humanBalsalazide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBalsalazide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinBalsalazide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299PTC299 may increase the nephrotoxic activities of Balsalazide.Investigational
PuromycinBalsalazide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Balsalazide.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Balsalazide.Approved
QuinineBalsalazide may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Balsalazide.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Balsalazide.Approved
RepaglinideBalsalazide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Balsalazide.Approved
ResveratrolResveratrol may increase the nephrotoxic activities of Balsalazide.Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Reteplase.Approved
ReviparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Reviparin.Approved
RibostamycinBalsalazide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Balsalazide.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Risedronate.Approved, Investigational
RivaroxabanBalsalazide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Rosiglitazone.Approved, Investigational
RosoxacinBalsalazide may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Balsalazide.Approved
SalicylamideSalicylamide may increase the nephrotoxic activities of Balsalazide.Approved
Salicylic acidSalicylic acid may increase the nephrotoxic activities of Balsalazide.Approved, Vet Approved
SalsalateSalsalate may increase the nephrotoxic activities of Balsalazide.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Balsalazide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Balsalazide.Investigational
SaxagliptinBalsalazide may increase the hypoglycemic activities of Saxagliptin.Approved
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Balsalazide.Investigational
SelexipagThe risk or severity of adverse effects can be increased when Balsalazide is combined with Selexipag.Approved
SeratrodastSeratrodast may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Balsalazide.Approved, Vet Approved
SisomicinBalsalazide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitagliptinBalsalazide may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SotalolBalsalazide may decrease the antihypertensive activities of Sotalol.Approved
SP1049CBalsalazide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinBalsalazide may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinBalsalazide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Balsalazide.Approved
SpironolactoneBalsalazide may decrease the antihypertensive activities of Spironolactone.Approved
SRT501SRT501 may increase the nephrotoxic activities of Balsalazide.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Streptokinase.Approved
StreptomycinBalsalazide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinBalsalazide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineBalsalazide may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleBalsalazide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the nephrotoxic activities of Balsalazide.Approved
SulfisoxazoleBalsalazide may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the nephrotoxic activities of Balsalazide.Approved
SulodexideBalsalazide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Balsalazide.Investigational
SunitinibBalsalazide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the nephrotoxic activities of Balsalazide.Approved, Withdrawn
TacrolimusBalsalazide may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Balsalazide.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Balsalazide.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Balsalazide.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Balsalazide.Approved, Investigational
TemafloxacinBalsalazide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Balsalazide.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tenecteplase.Approved
TenofovirThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may increase the nephrotoxic activities of Balsalazide.Approved
TepoxalinTepoxalin may increase the nephrotoxic activities of Balsalazide.Vet Approved
TeriflunomideTeriflunomide may increase the nephrotoxic activities of Balsalazide.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Balsalazide.Investigational
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Balsalazide.Approved
TicagrelorThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Balsalazide.Approved
TiludronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tiludronate.Approved, Vet Approved
TimololBalsalazide may decrease the antihypertensive activities of Timolol.Approved
TinoridineTinoridine may increase the nephrotoxic activities of Balsalazide.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tinzaparin.Approved
TioguanineThe metabolism of Tioguanine can be decreased when combined with Balsalazide.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Balsalazide.Approved
TixocortolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tixocortol.Approved
TobramycinBalsalazide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideBalsalazide may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideBalsalazide may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Balsalazide.Approved
TolmetinTolmetin may increase the nephrotoxic activities of Balsalazide.Approved
TorasemideBalsalazide may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Balsalazide.Approved
TranilastTranilast may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Balsalazide.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Balsalazide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Balsalazide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneBalsalazide may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Balsalazide.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Balsalazide.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the nephrotoxic activities of Balsalazide.Approved
TrovafloxacinBalsalazide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Balsalazide.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Balsalazide.Approved, Investigational
ValrubicinBalsalazide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Balsalazide.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Balsalazide.Approved
VerapamilVerapamil may increase the anticoagulant activities of Balsalazide.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Balsalazide.Approved
WarfarinBalsalazide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBalsalazide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Balsalazide may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Balsalazide.Approved
ZileutonZileuton may increase the nephrotoxic activities of Balsalazide.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Zoledronic acid.Approved
ZomepiracZomepirac may increase the nephrotoxic activities of Balsalazide.Withdrawn
ZorubicinBalsalazide may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Eckardt C. G. Wolf, Nageib Mohamed, Bhaskar Reddy Guntoori, “Safe process for the preparation of balsalazide.” U.S. Patent US07271253, issued September 18, 2007.

US07271253
General References
  1. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890 ]
  2. Ragunath K, Williams JG: Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther. 2001 Oct;15(10):1549-54. [PubMed:11563993 ]
External Links
ATC CodesA07EC04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (44.9 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8947
Blood Brain Barrier+0.7807
Caco-2 permeable-0.6455
P-glycoprotein substrateNon-substrate0.6247
P-glycoprotein inhibitor INon-inhibitor0.7877
P-glycoprotein inhibitor IINon-inhibitor0.7615
Renal organic cation transporterNon-inhibitor0.8312
CYP450 2C9 substrateNon-substrate0.7932
CYP450 2D6 substrateNon-substrate0.8255
CYP450 3A4 substrateNon-substrate0.5523
CYP450 1A2 substrateNon-inhibitor0.7689
CYP450 2C9 inhibitorNon-inhibitor0.7883
CYP450 2D6 inhibitorNon-inhibitor0.8726
CYP450 2C19 inhibitorNon-inhibitor0.8153
CYP450 3A4 inhibitorNon-inhibitor0.9537
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9196
Ames testNon AMES toxic0.5593
CarcinogenicityNon-carcinogens0.75
BiodegradationNot ready biodegradable0.5575
Rat acute toxicity1.9986 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9148
hERG inhibition (predictor II)Non-inhibitor0.7772
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc etobicoke site
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Salix pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral750 mg/1
TabletOral1.1 g/1
Tablet, film coatedOral1.1 g/1
Prices
Unit descriptionCostUnit
Colazal 750 mg capsule2.82USD capsule
Balsalazide disodium 750 mg capsule1.54USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6197341 No1998-03-132018-03-13Us
US7452872 Yes2007-02-242027-02-24Us
US7625884 Yes2007-02-242027-02-24Us
US8497256 No2011-06-232031-06-23Us
US9192616 No2006-08-022026-08-02Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityFreely soluble as disodium saltNot Available
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0621 mg/mLALOGPS
logP3.37ALOGPS
logP3.17ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.06ChemAxon
pKa (Strongest Basic)-0.033ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area148.65 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity94.37 m3·mol-1ChemAxon
Polarizability35.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a bezene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzobenzenes
Sub ClassNot Available
Direct ParentAzobenzenes
Alternative Parents
Substituents
  • Azobenzene
  • Beta amino acid or derivatives
  • Salicylic acid
  • Salicylic acid or derivatives
  • Hydroxybenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • Phenol
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous acid
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azo compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Tursi A: Balsalazide in treating colonic diseases. Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1555-63. doi: 10.1517/17425250903228842. [PubMed:19708827 ]
  2. Iacucci M, de Silva S, Ghosh S: Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol. 2010 Feb;24(2):127-33. [PubMed:20151072 ]
  3. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. [PubMed:16939423 ]
  4. Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12. [PubMed:18077625 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890 ]
  4. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F, Monteleone G: Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol. 2008 Feb 1;75(3):668-76. Epub 2007 Sep 29. [PubMed:17981262 ]
  5. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890 ]
  4. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890 ]
  2. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K: 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions. 1992;Spec No:C37-46. [PubMed:1359745 ]

Enzymes

Kind
Protein
Organism
Bacillus sp. (strain OY1-2)
Pharmacological action
unknown
Actions
substrate
General Function:
Azobenzene reductase activity
Specific Function:
Catalyzes the reductive cleavage of azo bond in aromatic azo compounds to the corresponding amines. Requires NADPH as an electron donor for its activity. Compounds with paired naphthalene groups coupled with the azo group are good substrates, with the following preference order: Rocceline > Sumifix Black B > Solar Orange.
Gene Name:
azr
Uniprot ID:
Q9FAW5
Molecular Weight:
19293.155 Da
References
  1. Ragunath K, Williams JG: Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther. 2001 Oct;15(10):1549-54. [PubMed:11563993 ]
  2. Ryan A, Laurieri N, Westwood I, Wang CJ, Lowe E, Sim E: A novel mechanism for azoreduction. J Mol Biol. 2010 Jul 2;400(1):24-37. doi: 10.1016/j.jmb.2010.04.023. Epub 2010 Apr 24. [PubMed:20417637 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54